---
company: DAVITA INC.
ticker: DVA
form: 8-K
filed: 2026-10-29
accepted: 2026-10-29T20:06:43+00:00
accession: 0000927066-26-000132
source: https://www.sec.gov/Archives/edgar/data/927066/000092706626000132/
quarterly_report: https://www.sec.gov/Archives/edgar/data/927066/000092706626000134/
---

# Davita (DVA) Q3 2026 earnings

## Header

- Company: Davita Inc.
- Reported: 2026-10-29 16:06 AMC ET
- Source: 8-K only — accession 0000927066-26-000132, Item 2.02 + Exhibit 99.1
- Verdict: Adjusted operating income of $561 million and adjusted diluted EPS of $3.82 reflect solid execution despite a $62 million goodwill impairment charge.

## Headline numbers

| Metric | Actual | YoY | QoQ | 8-K location |
|---|---:|---:|---:|---|
| Revenue | $3.578B | +4.8% | +0.7% | Ex. 99.1, Income Statement |

## Revenue breakdown

| Segment | Actual | YoY | Share of revenue | Note |
|---|---:|---:|---:|---|
| U.S. dialysis | $3.050B | +3.3% | 85.3% | Operating income $544M |
| Integrated kidney care | $144M | -11.1% | 4.0% | Operating loss $4M |
| International dialysis patient service and other | $398M | +3.1% | 11.1% | Operating loss $16M |

## Margins and costs

- Gross margin: N/A
- Operating expenses: $3.079B (+6.1% YoY)
- One-offs in the quarter: Goodwill and other asset impairment charges: $62M; Tax benefit on impairment: $1M; Noncontrolling interest credit on impairment: $34M
- Effective tax rate: 28.7% (prior-year 25.6%, year-to-date 26.5%)
- Non-GAAP bridge: Adds back goodwill and other asset impairments ($62M) and cybersecurity incident-related charges (none in Q3 2026).

## KPIs

| Metric | Actual | Prior quarter | Prior year | Change |
|---|---:|---:|---|---:|
| Total U.S. dialysis treatments | 7,329,644 | 7,226,600 | 7,284,517 | +1.4% vs prior Q, +0.6% vs prior Y |
| Average treatments per day | 92,780 | 92,649 | 92,447 | +0.1% vs prior Q, +0.3% vs prior Y |
| Normalized non-acquired treatment growth | 0.4% | 0.3% | N/A | +0.1 pp vs prior Q |
| Integrated kidney care patients | 80,800 | 64,900 | N/A | +24.5% vs prior Q |

## Guidance

| Metric | Guide | Prior guide | Change |
|---|---:|---:|---|
| Adjusted operating income | $2.175B - $2.250B | $2.150B - $2.250B | No change |
| Adjusted diluted net income per share attributable to DaVita Inc. | $14.30 - $15.20 | $14.10 - $15.20 | +$0.20 - $0.30 |
| Free cash flow | $1.000B - $1.250B | $1.000B - $1.250B | No change |

## What drove it

- Revenue story: Revenue increased 4.8% YoY and 0.7% QoQ, driven by normal fluctuations, increased average reimbursement rates, and improvements in payor mix.
- EPS story: Adjusted diluted EPS of $3.82 increased 86.7% YoY, driven by higher revenues and margins, partially offset by a $62 million goodwill impairment charge.
- One-off check: Goodwill and other asset impairment charges of $62 million (net of $1M tax benefit and $34M NCI credit).

## The good

- Adjusted operating income of $561M (+4.3% YoY)
- Adjusted diluted EPS of $3.82 (+86.7% YoY)
- Free cash flow of $276M (+75.5% YoY)
- Integrated kidney care patients increased to 80,800 (+24.5% YoY)

## The bad

- Operating income of $499M (-13.8% QoQ) due to $62M impairment charge
- GAAP diluted EPS of $3.40 (-15.4% QoQ)
- International dialysis operating loss of $16M

## The ugly

- Goodwill and other asset impairment charges of $62 million related to business in China

## Open questions

- The release does not provide specific guidance for GAAP operating income or diluted net income per share.
- The release does not provide a reconciliation of the current non-GAAP financial measures to the most directly comparable GAAP financial measures on a forward-looking basis.

## Full release

### Earnings: DVA — filed 2026-10-29

Davita Inc. (DVA) · Form 8-K, Item 2.02 · Filed 2026-10-29 · [SEC filing](https://www.sec.gov/Archives/edgar/data/927066/000092706626000132/)

Contact: Investor Relations

DaVita Inc. ir@davita.com

DaVita Inc. 3rd Quarter 2026 Results

Denver, Colorado, October 29, 2026 — DaVita Inc. (NYSE: DVA) announced financial and operating results for the quarter ended September 30, 2026.

Financial and operating highlights for the quarter ended September 30, 2026:

• Consolidated revenues were $3.578 billion.

• Operating income was $499 million and adjusted operating income was $561 million.

• Diluted earnings per share was $3.40 and adjusted diluted earnings per share was $3.82.

• Operating cash flow was $519 million and free cash flow was $276 million.

• Repurchased 0.6 million shares of the Company's common stock at an average price paid of $186.21 per share.

(1)

For definitions of non-GAAP financial measures, see the note titled "Note on Non-GAAP Financial Measures" and related reconciliations beginning on page¹⁴.

(1)

For definitions of non-GAAP financial measures, see the note titled "Note on Non-GAAP Financial Measures" and related reconciliations beginning on page¹⁴.

U.S. dialysis metrics:

Volume:

Total U.S. dialysis treatments for the third quarter of 2026 were 7,329,644, or an average of 92,780 treatments per day, representing a per day increase of 0.1% compared to the second quarter of 2026. Normalized non-acquired treatment growth in the third quarter of 2026 compared to the third quarter of 2025 was 0.4%.¹

Primary drivers of the changes in the table above were as follows:

Revenue:

The quarter change was primarily driven by normal fluctuations, partially offset by an increase in average reimbursement rates and improvements in payor mix. The year to date change was driven by typical annual rate increases and other normal fluctuations, partially offset by unfavorable changes in payor mix.

Patient care costs:

The quarter change was primarily due to increased medical supplies expenses. The year to date change was primarily driven by increased compensation expenses, medical supplies expense, insurance costs and health benefits expenses.

General and administrative:

The quarter change was primarily due to decreased professional fees. The year to date change was primarily driven by increases in IT-related costs and compensation expenses, partially offset by costs related to the cybersecurity incident experienced by the Company in 2025.

Certain items impacting the quarter:

Goodwill and other asset impairment charges.

During the quarter ended September 30, 2026, we recognized non-cash goodwill and other asset impairment charges related to our business in China. The effect was a $62 million impairment charge within operating income, offset by a $1 million tax benefit and $34 million noncontrolling interest credit, resulting in a $27 million net income impact attributable to DaVita Inc.

Share repurchases.

During the three months ended September 30, 2026, we repurchased 0.6 million shares for $111 million, at an average price paid of $186.21 per share.

Subsequent to September 30, 2026 through October 27, 2026, the Company has repurchased 0.5 million shares of our common stock for $87 million at an average price paid of $180.57 per share.

Financial and operating metrics:

(1)

For definitions of non-GAAP financial measures, see the note titled "Note on Non-GAAP Financial Measures" and related reconciliations beginning on page¹⁴.

(1)

For definitions of non-GAAP financial measures, see the note titled "Note on Non-GAAP Financial Measures" and related reconciliations beginning on page¹⁴.

Center activity:

As of September 30, 2026, we provided dialysis services to a total of approximately 298,100 patients at 3,269 outpatient dialysis centers, of which 2,671 centers were located in the United States and 598 centers were located in 14 countries outside of the United States.

Integrated kidney care (IKC):

As of September 30, 2026, we had approximately 80,800 patients in risk-based integrated care arrangements representing approximately $6.4 billion in annualized medical spend. We also had an additional 3,100 patients in other integrated care arrangements; we do not include the medical spend for these patients in this annualized medical spend estimate. For an additional description of these metrics, see footnote 5 in the "Supplemental Financial Data" table below.²

Outlook:

The following forward-looking measures and the underlying assumptions involve significant known and unknown risks and uncertainties, including those described below, and actual results may vary materially from these forward-looking measures. We do not provide guidance for operating income or diluted net income per share attributable to DaVita Inc. or operating cash flow on a basis consistent with United States generally accepted accounting principles (GAAP) nor a reconciliation of forward-looking non-GAAP financial measures to the most directly comparable GAAP financial measures on a forward-looking basis because we are unable to predict certain items contained in the GAAP measures without unreasonable efforts. These current non-GAAP financial measures do not include certain items, including goodwill impairment charges and foreign currency fluctuations, which may be significant. The guidance for our effective income tax rate on adjusted income attributable to DaVita Inc. also excludes the amount of third-party owners' income and related taxes attributable to non-tax paying entities.

The following table outlines normalized treatment days by quarter for 2025 and 2026. Normalized treatment days are adjusted for the mix of days of the week for each quarter and serve as a means to more readily compare calendar effects on each quarter's treatment volume.

Certain columns, rows or percentages may not sum or recalculate due to the presentation of rounded numbers.... (truncated)e call, please dial (877) 918-6630 from the U.S. or (517) 308-9042 from outside the U.S., and provide the operator the password "Earnings." This call is being webcast and can be accessed at the DaVita Investor Relations website investors.davita.com. A replay of the conference call will also be available at investors.davita.com.³

Forward looking statements

DaVita Inc. and its representatives may from time to time make written and oral forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA), including statements in this release, filings with the Securities and Exchange Commission (SEC), reports to stockholders and in meetings with investors and analysts. All statements in this release, during the related presentation or other meetings, other than statements of historical fact, are forward-looking statements and as such are intended to be covered by the safe harbor for "forward-looking statements" provided by the PSLRA. These forward-looking statements could include, among other things, statements about our balance sheet and liquidity, our expenses, revenues, billings and collections, patient census, the impact of the cybersecurity incident experienced by the Company in 2025 (cyber incident), the impact of federal government policy changes or shutdowns on our business, including with respect to federal funding and reimbursement rates of Medicare, Medicare Advantage (MA), Medicaid and other government programs, availability or cost of supplies, including without limitation the impact of evolving trade policies and tariffs and any reduction in clinical and other supplies due to any disruptions experienced by third party vendors, including with respect to our ability to provide home dialysis services, treatment volumes, mix expectation, such as the percentage or number of patients under commercial insurance, including potential impacts to such mix as a result of U.S. administration policies, current macroeconomic, marketplace and labor market conditions, and overall impact on our patients and teammates, as well as other statements regarding our outlook, future operations, financial condition and prospects, capital allocation plans, expenses, cost saving initiatives, other strategic initiatives, use of contract labor, government and commercial payment rates, expectations related to value-based care (VBC), integrated kidney care (IKC), MA plan enrollment and our international operations, expectations regarding increased competition and marketplace changes, including those related to new or potential entrants in the dialysis and pre-dialysis marketplace and the potential impact of innovative technologies, drugs, or other treatments on the dialysis industry, and expectations regarding our share repurchase program. All statements in this release, other than statements of historical fact, are forward-looking statements. Without limiting the foregoing, statements including the words "expect," "intend," "will," "could," "plan," "anticipate," "believe," "forecast," "guidance," "outlook," "goals," and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on DaVita's current expectations and are based solely on information available as of the date of this release. DaVita undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of changed circumstances, new information, future events or otherwise, except as may be required by law. Actual future events and results could differ materially from any forward-looking statements due to numerous factors that involve substantial known and unknown risks and uncertainties. These risks and uncertainties include, among other things:

• external conditions, including those related to general economic, political and global health conditions, including without limitation, the impact of global events and political or governmental volatility, including in the Middle East and Ukraine; the impact of the domestic political environment and related developments on the current healthcare marketplace, our patients and on our business; the impact of infectious diseases or other adverse conditions on our financial condition, the chronic kidney disease population and our patient population; supply chain challenges and disruptions, including without limitation, with respect to certain key services, critical clinical supplies and equipment we obtain from third parties, and including any impacts on our supply chain and cost of supplies as a result of global events, natural disasters or evolving trade policies, including tariffs; the impact on our patients and industry of continued increased competition from dialysis providers and others, including new or potential entrants in the dialysis and pre-dialysis marketplace; the impact of new or innovative technologies, drugs, or other treatments, including our ability to successfully implement new technologies, treatments or therapies in our business such as those related to middle molecule toxin clearance; elevated teammate turnover or labor costs; and our ability to respond to challenging U.S. and global economic and marketplace conditions, including, among other things, our ability to successfully identify cost saving opportunities and execute on related strategic initiatives;

• the concentration of profits generated by higher-paying commercial payor plans for which there is continued downward pressure on average realized payment rates; our ability to negotiate and maintain contracts with these payors on competitive terms or at all; a reduction in the number or percentage of our patients under commercial plans, including, without limitation, as a result of healthcare, immigration or other policies implemented by the U.S. administration, continuing legislative, regulatory or other... (truncated), or as a result of payors implementing restrictive plan designs or resulting from negotiations with large commercial payors that we have in the past, and currently are, conducting on a concurrent basis;

• risks arising from laws, regulations or requirements applicable to us or changes thereto, including, without limitation, the One Big Beautiful Bill Act and those related to trade policy, healthcare, charitable premium assistance, privacy, antitrust matters, and acquisition, merger, joint venture or similar transactions and/or labor matters, and potential impacts of changes in interpretation or enforcement thereof or related litigation impacting, among other things, coverage or reimbursement rates for our services or the number of patients enrolled in or that select higher-paying⁴ commercial plans, and the risk that we make incorrect assumptions about how our patients will respond to any such developments;

• our ability to successfully implement our strategies with respect to IKC and VBC initiatives that may be impacted by, among other things, changes to the Comprehensive Kidney Care Contracting model and home based dialysis in the desired time frame and in a complex, dynamic and highly regulated environment;

• a reduction in government payment rates under the Medicare End Stage Renal Disease program, state Medicaid or other government-based programs and the impact of the MA benchmark structure and adjustment methodologies;

• our reliance on significant suppliers, service providers and other third party vendors to provide key support to our business operations and enable our provision of services to patients, including, among others, suppliers of certain pharmaceuticals, administrative or other services or critical clinical products; and risks resulting from a closure, reduction, disruption or transition in the services or products provided to us by such suppliers, service providers and third party vendors, which may, among other things, increase our costs or expenses;

• our ability to successfully and cost-effectively maintain, operate or upgrade our information systems or those of third-party service providers upon which we rely and our ability to successfully and cost-effectively adopt or adapt to new technologies, treatments or therapies, including technologies that utilize artificial intelligence;

• legal and compliance risks, such as compliance with complex, and at times, evolving government regulations and requirements, and with additional laws that may apply to our operations as we expand geographically or enter into new lines of business;

• noncompliance by us or our business associates with any privacy or security laws or any security breach by us or a third party, such as the cyber incident, including, among other things, any such non-compliance or breach involving the misappropriation, loss or other unauthorized use or disclosure of confidential information;

• our ability to attract, retain and motivate teammates, including key leadership personnel, our ability to manage potential disruptions to our business and operations, including potential work stoppages, and our ability to manage operating cost increases or productivity decreases that may be related to political unrest, legislative or other changes, union organizing activities, or volatility and uncertainty in the current challenging and highly competitive labor market that has experienced an ongoing nationwide shortage of skilled clinical personnel, among other things;

• changes in practice patterns, pricing, or reimbursement and payment policies or processes related to pharmaceuticals, medical equipment or supplies, including with respect to oral phosphate binders, among other things;

• our ability to develop and maintain relationships with physicians and hospitals, changing affiliation models for physicians, and the emergence of new models of care or other initiatives that, among other things, may erode our patient base and impact reimbursement rates;

• our ability to complete and successfully integrate and operate acquisitions, mergers, dispositions, joint ventures or other strategic transactions on terms favorable to us or at all; and our ability to continue to successfully expand our operations and services in markets outside the United States, or to businesses or products outside of dialysis services;

• the variability of our cash flows, including, without limitation, any extended billing or collections cycles that may be due to, among other things, defects or operational issues in our billing systems such as those experienced during the cyber incident, or defects or operational issues in the billing systems or services of third parties on which we rely; the risk that we may not be able to generate or access sufficient cash in the future to service our indebtedness or to fund our other liquidity needs;

• the effects on us or others of natural or other disasters, public health crises or severe adverse weather events such as hurricanes, earthquakes, fires or flooding;

• factors that may impact our ability to repurchase stock under our share repurchase program and the timing of any such stock repurchases, as well as any use by us of a considerable amount of available funds to repurchase stock;

• our goals and disclosures related to sustainability matters, including, among other things, evolving regulatory requirements affecting environmental, social and governance standards, measurements and reporting requirements; and

• the other risk factors, trends and uncertainties set forth in our Annual Report on Form 10-K for the year ended December 31, 2025 and Quarterly Reports on Form 10-Q for the quarters ended March 31 and June 30, 2026, and the risks and uncertainties discussed in any subsequent reports that we file or furnish with the SEC from time to time.... (truncated)rising prior to the filing of the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2026.⁵

#### Financial statements

##### Income Statement (Three months ended — For definitions of non-GAAP financial measures, see the note titled "Note on Non-GAAP Financial Measures" and related reconciliations beginning on page 14 . (in millions))

| | Three months ended – September 30, 2026 – Amount | Three months ended – September 30, 2026 – Margin | Three months ended – June 30, 2026 – Amount | Three months ended – June 30, 2026 – Margin | Nine months ended September 30, – 2026 – Amount | Nine months ended September 30, – 2025 – Margin | Nine months ended September 30, – 2025 – Amount | Nine months ended September 30, – Margin |
|---|---:|---:|---:|---:|---:|---:|---:|---:|
| Operating income | 499 | 14 | 579 | 16.3 | 1,560 | 14.8 | 1,483 | 14.8 |
| Adjusted operating income(1) | 561 | 15.7 | 579 | 16.3 | 1,622 | 15.4 | 1,508 | 15 |

##### Income Statement (Three months ended September 30, — (dollars and shares in thousands, except per share data))

| | Three months ended September 30, – 2026 | Three months ended September 30, – 2025 | Nine months ended September 30, – 2026 | Nine months ended September 30, – 2025 |
|---|---:|---:|---:|---:|
| Dialysis patient service revenues | 3,408,266 | 3,298,090 | 10,047,440 | 9,607,954 |
| Other revenues | 169,860 | 122,137 | 500,318 | 415,328 |
| Total revenues | 3,578,126 | 3,420,227 | 10,547,758 | 10,023,282 |
| **Operating expenses:** | | | | |
| Patient care costs | 2,451,047 | 2,332,759 | 7,185,305 | 6,833,959 |
| General and administrative | 408,697 | 414,373 | 1,254,069 | 1,201,268 |
| Depreciation and amortization | 165,188 | 177,490 | 510,825 | 528,645 |
| Equity investment income, net | -8,237 | -10,162 | -24,765 | -23,135 |
| Goodwill and other asset impairment charges | 62,176 |  | 62,176 |  |
| Total operating expenses | 3,078,871 | 2,914,460 | 8,987,610 | 8,540,737 |
| Operating income | 499,255 | 505,767 | 1,560,148 | 1,482,545 |
| Debt expense | -150,016 | -150,557 | -445,403 | -431,674 |
| Debt extinguishment and modification costs |  | -5,150 | -2,035 | -5,150 |
| Other income (loss), net | 9,468 | -41,257 | 22,241 | -81,657 |
| Income before income taxes | 358,707 | 308,803 | 1,134,951 | 964,064 |
| Income tax expense | 89,318 | 68,554 | 247,304 | 216,379 |
| Net income | 269,389 | 240,249 | 887,647 | 747,685 |
| Less: Net income attributable to noncontrolling interests | -46,458 | -89,917 | -201,789 | -235,099 |
| Net income attributable to DaVita Inc. | 222,931 | 150,332 | 685,858 | 512,586 |
| **Earnings per share attributable to DaVita Inc.:** | | | | |
| Basic net income | 3.49 | 2.09 | 10.5 | 6.77 |
| Diluted net income | 3.4 | 2.04 | 10.27 | 6.62 |
| **Weighted average shares for earnings per share:** | | | | |
| Basic shares | 63,835 | 72,075 | 65,322 | 75,768 |
| Diluted shares | 65,504 | 73,769 | 66,811 | 77,442 |

##### Income Statement (Three months ended — (unaudited) (dollars in millions and shares in thousands, except per treatment and patient data))

| | Three months ended – September 30, 2026 | Three months ended – June 30, 2026 | Nine months ended September 30, 2026 |
|---|---:|---:|---:|
| **1. Consolidated business metrics:** | | | |
| Operating margin | 14 | 16.3 | 14.8 |
| Adjusted operating margin excluding certain items(1) | 15.7 | 16.3 | 15.4 |
| General and administrative expenses as a percent of consolidated revenues(2) | 11.4 | 11.9 | 11.9 |
| Effective income tax rate on income | 24.9 | 21.1 | 21.8 |
| Effective income tax rate on income attributable to DaVita Inc.(1) | 28.7 | 25.6 | 26.5 |
| Effective income tax rate on adjusted income attributable to DaVita Inc.(1) | 26.6 | 25.6 | 25.8 |
| **Revenues:** | | | |
| U.S. dialysis patient services and other | 3,050 | 3,012 | 9,004 |
| **Other—Ancillary services** | | | |
| Integrated kidney care | 144 | 162 | 422 |
| Other U.S. ancillary | 10 | 9 | 29 |
| International dialysis patient service and other | 398 | 386 | 1,156 |
|  | 552 | 557 | 1,606 |
| Eliminations | -24 | -14 | -62 |
| Total consolidated revenues | 3,578 | 3,554 | 10,548 |
| **Operating income (loss):** | | | |
| U.S. dialysis | 544 | 538 | 1,588 |
| **Other—Ancillary services** | | | |
| Integrated kidney care | 4 | 40 | 24 |
| Other U.S. ancillary | -6 | -8 | -20 |
| International | -16 | 25 | 40 |
|  | -19 | 57 | 44 |
| Corporate administrative support expenses | -26 | -16 | -72 |
| Total consolidated operating income | 499 | 579 | 1,560 |

##### Income Statement (Three months ended — (dollars in millions and shares in thousands, except per treatment and patient data))

| | Three months ended – September 30, 2026 | Three months ended – June 30, 2026 | Nine months ended September 30, 2026 |
|---|---:|---:|---:|
| **Revenue:** | | | |
| Dialysis patient service revenues | 3,044 | 3,005 | 8,984 |
| Other revenues | 7 | 7 | 20 |
| Total operating revenues | 3,050 | 3,012 | 9,004 |
| **Operating expenses:** | | | |
| Patient care costs | 2,054 | 2,005 | 6,028 |
| General and administrative | 316 | 331 | 967 |
| Depreciation and amortization | 144 | 146 | 446 |
| Equity investment income | -8 | -8 | -25 |

##### Income Statement (Twelve months ended)

| | Twelve months ended – September 30, 2026 | September 30, 2026 | Twelve months ended – September 30, 2026 | September 30, 2026 | Twelve months ended – June 30, 2026 | June 30, 2026 | Twelve months ended – June 30, 2026 | June 30, 2026 |
|---|---:|---:|---:|---:|---:|---:|---:|---:|
| Net income from continuing operations attributable to DaVita Inc. |  |  | 895 |  |  |  | 822 |  |
| Income taxes | 324 |  |  |  | 303 |  |  |  |
| Interest expense | 543 |  |  |  | 540 |  |  |  |
| Depreciation and amortization | 698 |  |  |  | 710 |  |  |  |
| Impairment charges | 62 |  |  |  |  |  |  |  |
| Net income attributable to noncontrolling interests | 299 |  |  |  | 342 |  |  |  |
| Stock-settled stock-based compensation | 117 |  |  |  | 127 |  |  |  |
| Debt extinguishment and modification costs | 11 |  |  |  | 16 |  |  |  |
| Expected cost savings and expense reductions | 10 |  |  |  | 7 |  |  |  |
| Other | 84 |  |  |  | 149 |  |  |  |
| Consolidated EBITDA |  |  | 3,042 |  |  |  | 3,018 |  |
| Total debt, excluding debt discount and other deferred financing costs(1) |  |  |  | 10,832 |  |  |  | 10,848 |
| Less: Cash and cash equivalents including short-term investments(2) |  | -563 |  |  |  | -685 |  |  |
| Consolidated net debt |  |  |  | 10,269 |  |  |  | 10,162 |
| Last twelve months Consolidated EBITDA |  |  |  | 3,042 |  |  |  | 3,018 |
| Leverage ratio |  | 3.38x |  |  |  | 3.37x |  |  |
| Maximum leverage ratio permitted under the Credit Agreement |  | 5.00x |  |  |  | 5.00x |  |  |

##### Income Statement (Three months ended — Adjusted net income and adjusted diluted net income per share attributable to DaVita Inc.:)

| | Three months ended – September 30, 2026 – Dollars | Three months ended – September 30, 2026 – Per share | Three months ended – June 30, 2026 – Dollars | Three months ended – June 30, 2026 – Per share | Nine months ended – September 30, 2026 – Dollars | Nine months ended – September 30, 2025 – Per share | Nine months ended – September 30, 2025 – Dollars | Nine months ended – Per share |
|---|---:|---:|---:|---:|---:|---:|---:|---:|
| **Consolidated:** | | | | | | | | |
| Net income attributable to DaVita Inc. | 223 | 3.4 | 265 | 4.02 | 686 | 10.27 | 513 | 6.62 |
| Goodwill and other asset impairments(1) | 62 | 0.95 |  |  | 62 | 0.93 |  |  |
| Goodwill and other asset impairments attributable to noncontrolling interests(1) | -34 | -0.53 |  |  | -34 | -0.51 |  |  |
| Cybersecurity incident-related charges(2) |  |  |  |  |  |  | 25 | 0.33 |
| Other loss, net - Mozarc net loss(3) |  |  |  |  |  |  | 26 | 0.33 |
| Income tax impact related to prior legal matter(4) |  |  |  |  |  |  | 19 | 0.24 |
| Related income tax | -1 | -0.01 |  |  | -1 | -0.01 | -6 | -0.08 |
| Adjusted net income attributable to DaVita Inc. | 250 | 3.82 | 265 | 4.02 | 713 | 10.67 | 576 | 7.44 |

##### Income Statement (Three months ended September 30, 2026 — Adjusted operating income:)

| | Three months ended September 30, 2026 – U.S. dialysis | Three months ended September 30, 2026 – Ancillary services – U.S. IKC | Three months ended September 30, 2026 – Ancillary services – U.S. Other | Three months ended September 30, 2026 – Ancillary services – International | Three months ended September 30, 2026 – Ancillary services – Total | Three months ended September 30, 2026 – Corporate administration | Three months ended September 30, 2026 – Consolidated |
|---|---:|---:|---:|---:|---:|---:|---:|
| Operating income (loss) | 544 | 4 | -6 | -16 | -19 | -26 | 499 |
| Goodwill and other asset impairments(1) |  |  |  | 62 | 62 |  | 62 |
| Adjusted operating income (loss) | 544 | 4 | -6 | 46 | 44 | -26 | 561 |

##### Income Statement (Nine months ended September 30, 2026 — Certain columns, rows or percentages may not sum or recalculate due to the presentation of rounded numbers.)

| | Nine months ended September 30, 2026 – U.S. dialysis | Nine months ended September 30, 2026 – Ancillary services – U.S. IKC | Nine months ended September 30, 2026 – Ancillary services – U.S. Other | Nine months ended September 30, 2026 – Ancillary services – International | Nine months ended September 30, 2026 – Ancillary services – Total | Nine months ended September 30, 2026 – Corporate administration | Nine months ended September 30, 2026 – Consolidated |
|---|---:|---:|---:|---:|---:|---:|---:|
| Operating income (loss) | 1,588 | 24 | -20 | 40 | 44 | -72 | 1,560 |
| Goodwill and other asset impairments(1) |  |  |  | 62 | 62 |  | 62 |
| Adjusted operating income (loss) | 1,588 | 24 | -20 | 102 | 106 | -72 | 1,622 |

##### Income Statement (Three months ended — Effective income tax rates:)

| | Three months ended – September 30, 2026 | Three months ended – June 30, 2026 | Nine months ended September 30, 2026 |
|---|---:|---:|---:|
| **Effective income tax rates on income attributable to DaVita Inc.:** | | | |
| Income before income taxes | 359 | 435 | 1,135 |
| Noncontrolling owners’ income primarily attributable to non-tax paying entities | -46 | -78 | -202 |
| Income before income taxes attributable to DaVita Inc. | 313 | 357 | 933 |
| Income tax expense | 89 | 92 | 247 |
| Income tax benefit (expense) attributable to noncontrolling interests | 1 | -1 |  |
| Income tax expense attributable to DaVita Inc. | 90 | 91 | 247 |
| Effective income tax rate on income attributable to DaVita Inc. | 28.7 | 25.6 | 26.5 |
| **Effective income tax rate on adjusted income attributable to DaVita Inc.:** | | | |
| Income before income taxes | 359 | 435 | 1,135 |
| Goodwill and other asset impairments(1) | 62 |  | 62 |
| Noncontrolling owners’ income primarily attributable to non-tax paying entities | -46 | -78 | -202 |
| Goodwill and other asset impairments attributable to noncontrolling interests(1) | -34 |  | -34 |
| Adjusted income before income taxes attributable to DaVita Inc. | 341 | 357 | 961 |
| Income tax expense | 89 | 92 | 247 |
| **Income tax benefit (expense) related to:** | | | |
| Goodwill and other asset impairments | 1 |  | 1 |
| Noncontrolling interests | 1 | -1 |  |
| Income tax on adjusted income attributable to DaVita Inc. | 90 | 91 | 248 |
| Effective income tax rate on adjusted income attributable to DaVita Inc. | 26.6 | 25.6 | 25.8 |

##### Balance Sheet (September 30, 2026 — (dollars and shares in thousands, except per share data))

| | September 30, 2026 | December 31, 2025 |
|---|---:|---:|
| **ASSETS** | | |
| Cash and cash equivalents | 495,629 | 676,438 |
| Restricted cash and equivalents | 83,631 | 81,309 |
| Short-term investments | 70,673 | 24,303 |
| Accounts receivable | 2,509,014 | 2,414,690 |
| Inventories | 161,464 | 160,627 |
| Contract assets and other receivables | 565,459 | 494,414 |
| Prepaid and other current assets | 141,147 | 156,285 |
| Income tax receivable | 47,807 | 49,937 |
| Total current assets | 4,074,824 | 4,058,003 |
| Property and equipment, net of accumulated depreciation of $6,985,414 and $6,602,134, respectively | 2,731,171 | 2,812,966 |
| Operating lease right-of-use assets | 2,434,212 | 2,397,179 |
| Intangible assets, net of accumulated amortization of $39,378 and $37,751, respectively | 221,070 | 222,125 |
| Equity method and other investments | 404,305 | 157,249 |
| Long-term investments | 38,382 | 40,966 |
| Other long-term assets | 364,506 | 246,520 |
| Goodwill | 7,548,042 | 7,545,095 |
|  | 17,816,512 | 17,480,103 |
| **LIABILITIES AND EQUITY** | | |
| Accounts payable | 662,199 | 696,148 |
| Other liabilities | 848,178 | 893,024 |
| Accrued compensation and benefits | 747,911 | 793,478 |
| Current portion of operating lease liabilities | 438,132 | 425,484 |
| Current portion of long-term debt | 112,491 | 109,201 |
| Income tax payable | 23,143 | 24,359 |
| Due to related party | 54,714 | 199,940 |
| Total current liabilities | 2,886,768 | 3,141,634 |
| Long-term operating lease liabilities | 2,185,179 | 2,175,658 |
| Long-term debt | 10,656,624 | 10,163,988 |
| Other long-term liabilities | 100,431 | 83,516 |
| Deferred income taxes | 861,693 | 756,869 |
| Total liabilities | 16,690,695 | 16,321,665 |
| **Commitments and contingencies** | | |
| Noncontrolling interests subject to put provisions | 1,484,283 | 1,532,166 |
| **Equity:** | | |
| Common stock ($0.001 par value, 450,000 shares authorized; 69,237 shares issued and 63,400 shares outstanding at September 30, 2026, and 68,549 shares issued and outstanding at December 31, 2025) | 69 | 69 |
| Additional paid-in capital | 53,979 |  |
| Accumulated earnings (deficit) | 301,565 | -328,428 |
| Treasury stock (5,837 and zero shares, respectively) | -917,239 | -199,940 |
| Accumulated other comprehensive loss | -29,461 | -122,783 |
| Total DaVita Inc. shareholders' equity deficit | -591,087 | -651,082 |
| Noncontrolling interests not subject to put provisions | 232,621 | 277,354 |
| Total equity deficit | -358,466 | -373,728 |
|  | 17,816,512 | 17,480,103 |

##### Cash Flow (Nine months ended September 30, — (dollars in thousands))

| | Nine months ended September 30, – 2026 | Nine months ended September 30, – 2025 |
|---|---:|---:|
| **Cash flows from operating activities:** | | |
| Net income | 887,647 | 747,685 |
| **Adjustments to reconcile net income to net cash provided by operating activities:** | | |
| Depreciation and amortization | 510,825 | 528,645 |
| Goodwill and other asset impairment charges | 62,176 |  |
| Loss on extinguishment of debt |  | 4,253 |
| Stock-based compensation expense | 83,378 | 101,559 |
| Deferred income taxes | 91,207 | 68,989 |
| Equity investment loss, net | 887 | 91,532 |
| Other non-cash losses, net | 14,668 | 11,522 |
| **Changes in operating assets and liabilities, net of effect of acquisitions and divestitures:** | | |
| Accounts receivable | -67,585 | -144,688 |
| Inventories | 1,103 | 913 |
| Other current assets | -50,210 | -153,428 |
| Other long-term assets | -47,733 | -21 |
| Accounts payable | -47,803 | 97,879 |
| Accrued compensation and benefits | -64,671 | 19,279 |
| Other current liabilities | -50,713 | 16,462 |
| Income taxes | 453 | -30,635 |
| Other long-term liabilities | 6,101 | -14,172 |
| Net cash provided by operating activities | 1,329,730 | 1,345,774 |
| **Cash flows from investing activities:** | | |
| Additions of property and equipment | -431,323 | -430,434 |
| Acquisitions | -41,693 | -118,337 |
| Proceeds from asset and business sales | 16,297 | 32,337 |
| Purchase of debt investments held-to-maturity | -66,788 | -15,842 |
| Purchase of other debt and equity investments | -29,832 | -3,352 |
| Proceeds from debt investments held-to-maturity | 17,020 | 38,051 |
| Proceeds from sale of other debt and equity investments | 4,382 | 6,706 |
| Purchase of equity method investments | -221,839 | -2,466 |
| Distributions from equity method investments | 329 | 1,514 |
| Net cash used in investing activities | -753,447 | -491,823 |
| **Cash flows from financing activities:** | | |
| Borrowings | 3,511,331 | 4,672,170 |
| Payments on long-term debt | -3,021,008 | -3,880,721 |
| Deferred and debt related financing costs | -10,602 | -26,416 |
| Purchase of treasury stock from related party | -419,318 | -430,286 |
| Other purchases of treasury stock | -450,862 | -1,033,887 |
| Distributions to noncontrolling interests | -243,786 | -232,721 |
| Net proceeds from issuance of common stock under employee stock plans | 14,509 | 17,583 |
| Payment of tax withholdings on net share settlements of equity awards | -68,968 | -33,764 |
| Contributions from noncontrolling interests | 4,636 | 3,999 |
| Proceeds from sales of additional noncontrolling interests |  | 169 |
| Purchases of noncontrolling interests | -70,593 | -16,385 |
| Net cash used in financing activities | -754,661 | -960,259 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | -109 | 21,897 |
| Net decrease in cash, cash equivalents and restricted cash | -178,487 | -84,411 |
| Cash, cash equivalents and restricted cash at beginning of the year | 757,747 | 879,825 |
| Cash, cash equivalents and restricted cash at end of the period | 579,260 | 795,414 |

##### Cash Flow (Three months ended — Free cash flow:)

| | Three months ended – September 30, 2026 | Three months ended – June 30, 2026 | Three months ended – September 30, 2025 | Nine months ended September 30, 2026 |
|---|---:|---:|---:|---:|
| Net cash provided by operating activities | 519 | 490 | 842 | 1,330 |
| **Adjustments to reconcile net cash provided by operating activities to free cash flow:** | | | | |
| Distributions to noncontrolling interests | -94 | -64 | -82 | -244 |
| Contributions from noncontrolling interests |  |  | 1 | 5 |

##### Cash Flow (Twelve months ended — Certain columns or rows may not sum or recalculate due to the presentation of rounded numbers.)

| | Twelve months ended – September 30, 2026 | Twelve months ended – June 30, 2026 | Twelve months ended – September 30, 2025 |
|---|---:|---:|---:|
| Net cash provided by operating activities | 1,870 | 2,193 | 1,893 |
| **Adjustments to reconcile net cash provided by operating activities to free cash flow:** | | | |
| Distributions to noncontrolling interests | -335 | -323 | -341 |
| Contributions from noncontrolling interests | 8 | 9 | 8 |
| Maintenance capital expenditures(5) | -417 | -424 | -423 |
| Development capital expenditures(6) | -160 | -159 | -178 |
| Proceeds from sale of self-developed properties | 14 | 12 | 36 |
| Free cash flow | 980 | 1,308 | 996 |

##### Income Statement (dollars in millions, except per share data)

| | Low – Current 2026 guidance | High – Current 2026 guidance | Low – Prior 2026 guidance | High – Prior 2026 guidance |
|---|---:|---:|---:|---:|
| Adjusted operating income | 2,175 | 2,250 | 2,150 | 2,250 |
| Adjusted diluted net income per share attributable to DaVita Inc. | 14.3 | 15.2 | 14.1 | 15.2 |
| Free cash flow | 1,000 | 1,250 | 1,000 | 1,250 |
